Form 4: Vaxart CSO Sean Tucker's RSU Tax Withholding

Vaxart's Chief Scientific Officer, Sean Tucker, reported the withholding of 36,418 common shares to cover tax obligations related to vested Restricted Stock Units.

Summary

• Sean Tucker, SVP, Chief Scientific Officer of Vaxart, Inc. (VXRT), reported a transaction on March 24, 2026.
• 36,418 shares of common stock were disposed of at a price of $0.694 per share.
• This disposition was due to the withholding of shares by Vaxart to satisfy income tax obligations in connection with the net settlement of Restricted Stock Units (RSUs) that vested on March 24, 2026.
• Following this transaction, Sean Tucker directly beneficially owns 886,735 shares of common stock.
• Additionally, 51,465 shares are indirectly owned by joint tenancy with Frances Chang and Sean Tucker, and 9,060 shares are indirectly owned by spouse.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and RSU vesting, which can be seen as a retention mechanism for key personnel.

Positives

• Vesting of Restricted Stock Units (RSUs) for a key executive, Sean Tucker, indicates continued compensation and retention of talent within Vaxart.

Negatives

• No direct negatives identified for the company; the transaction is a routine tax withholding event.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax withholding are standard practices in executive compensation across various industries, particularly in biotech where equity compensation is common. This transaction is a routine event and does not indicate any specific industry trend or competitive action.

Comparison to Industry Standards

• RSU vesting and tax withholding are standard compensation practices for executives in publicly traded companies, aligning with typical industry compensation structures.
• The reported share price of $0.694 for tax purposes is specific to Vaxart's stock valuation at the time of vesting and is not directly comparable to other companies' stock prices without further context.

Stakeholder Impact

• Shareholders: Minimal direct impact as it is a routine compensation event. The slight reduction in direct ownership for tax purposes is offset by the executive's continued equity stake.
• Employees: No direct impact on the broader employee base is mentioned in this filing.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding event related to RSU vesting for a key executive. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for buying or selling.

Keywords

Vaxart, VXRT, Sean Tucker, Form 4, insider transaction, RSU, Restricted Stock Units, tax withholding, Chief Scientific Officer